Patricia Aspichueta - Nursing Science

Author Information

Patricia Aspichueta is affiliated with the Department of Physiology at the Faculty of Medicine and Nursing, University of the Basque Country in Leioa, Bizkaia, Spain. She is also associated with the Biocruces Health Research Institute in Barakaldo, Spain.

Research Contributions

Patricia Aspichueta has made significant contributions to the field of hepatology and metabolic diseases. Her research primarily focuses on liver diseases, including nonalcoholic fatty liver disease (NAFLD) and cholangiocarcinoma. She has explored various mechanisms driving these diseases, such as lipid metabolism, protein modifications like neddylation, and the role of dietary factors. Her work has implications for the development of potential therapeutic strategies for obesity, liver steatosis, and liver cancers.

Aliases

P Aspichueta, Patricia Aspichueta

Publication and Citation Metrics

Metric	Value
Citation Count	2966
H-index	30
Paper Count	140

Publications:

Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

DOI: 10.1038/s41467-022-28749-z

Year: 2022

Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.

DOI: 10.1016/j.jhep.2022.02.007

Year: 2022

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.

DOI: 10.1002/hep.32344

Year: 2022

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

DOI: 10.1016/j.molmet.2021.101275

Year: 2021

Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice.

DOI: 10.1016/j.aohep.2021.100357

Year: 2021

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)

DOI: 10.3390/biomedicines9101289

Year: 2021

E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

DOI: 10.1158/0008-5472.CAN-20-2052

Year: 2021

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.

DOI: 10.1016/j.jhep.2021.09.008

Year: 2021

Inhibition of ATG3 ameliorates liver steatosis by increasing SIRT1 in an autophagic-independent action

DOI: 10.1530/ENDOABS.73.AEP252

Year: 2021

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects

DOI: 10.1111/liv.14898

Year: 2021

What Role do Parents Play in Pediatric Units?

How Does Funding Enhance Patient Care Quality?

Who Makes Up a Multidisciplinary Team?

What are the most commonly used devices in nursing?

What are the Different Levels of CPR Certification?

What are the Key Features to Look for in Nursing Footwear?

Who is Eligible for SLRP?

What is SPF and How Much is Needed?

What are Common Work-Life Balance Policies in Nursing?

How Does Mentorship Benefit Mentors?

Partnered Content Networks

Relevant Topics